Clostridium difficile Infection: Diagnosis and Management

Brian Viviano D.O.

Objectives

▶ Identify patients at increased risk of C-diff infection

▶ Pathogenesis of C-diff

▶ Identify best tests for diagnosis of C-diff

▶ Define fulminant C-diff and compare treatment strategies

▶ Treatment, prevention and control of C-diff and recurrent C-diff

Case study

▶ 42 year old female with history of essential hypertension and COPD presents to ED complaining of 24 hours of intractable, diffuse abdominal pain and diarrhea. Patient reports 10-12 foul smelling stools over the previous 24 hours. Blood work revealed WBC-24,000 and CT showed diffuse colonic thickening. Patient has been in normal health with the exception of a URI treated with antibiotic 6 weeks ago.

Pseudomembranous colitis- cont'd

(Left) Axial CT scan of the midabdomen utilizing oral but not intravenous contrast demonstrates marked thickening of the colonic wall (white arrows) producing the so-called "accordion sign." There is a small amount of pericolonic stranding (red arrow) and ascites (green arrow). **(Right)** Axial CT scan through the pelvis shows marked thickening of the wall of the rectum (yellow arrows) indicating this is a pan-colitis.

Clostridium Difficile

- Spore-forming rod
- Infection typically follows use of broad spectrum antibiotics- ampicillin, clindamycin, cephalosporins
  - Wipe out the normal intestinal bacterial flora, allowing the pathogenic Clostridium difficile to superinfect the colon
- Symptoms are causes by exotoxins
  - Toxin A- causes diarrhea
  - Toxin B- cytotoxic to colonic cells

Associated antibiotics

| Low risk	Medium risk	High risk
Aminoglycosides	Co-amoxiclav	Second/third generation cephalosporins
Vancomycin	Macrolides	Clindamycin
Trimethoprim	Amoxicillin/ampicillin	Fluoroquinolones
Tetracyclines		
Piptazobactam		
Benzylpenicillin		

Clostridium difficile

▶ Infection is defined by the presence of symptoms (diarrhea) and either a positive stool toxin or colonoscopic/histologic findings consistent with pseudomembranous colitis (next slide).

▶ Presence of symptoms are necessary and patients without symptoms should not be tested as they can be carriers and do not require treatment.

    ▶ Unnecessary cost and treatment

Pseudomembranous colitis

Endothelial damage from the initial event or disease process causes small areas of necrosis in the surface epithelium. The eruption of neutrophils, nuclear debris, and other inflammatory elements from the lamina propria onto the epithelium then leads to pseudomembrane formation.

Estimated Annual U.S. Burden

Estimated U.S. Burden of CDI, According to the Location of Stool Collection and Inpatient Health Care Exposure, 2011.

CO-HCA: Community onset healthcare-associated
NHO: Nursing home onset
HO: Hospital onset

1. Lessa et al. N Engl J Med 2015; 372(9):825-834.

2. Dubberke et al. Clin Infect Dis 2012; 55:S88-92.

- **453,000 CDI cases[1]**
  - **293,000 healthcare-associated**
    - 107,000 hospital-onset
    - 104,000 nursing home-onset
    - 81,000 community-onset, healthcare-facility associated
  - **160,000 community-associated**
    - 82% associated with outpatient healthcare exposure
  - *Overall, 94% of CDI cases related to healthcare*
- **29,000 deaths**
- **$4.8 billion in excess healthcare costs[2]**

Clostridium difficile- Incidence

- An estimated 500,000 cases yearly in United States
- Increased risk with the following
  - Age > 65
  - Female
  - Caucasian
  - Healthcare exposure
  - Antibiotic exposure
  - Inflammatory bowel disease- also carries increased risk of recurrence and colectomy
  - PPI?- 50% increase risk of recurrence
  - Stem cell (9-fold increased risk) and solid organ transplant recipients (5-fold increased risk)
  - ESRD on dialysis. (2-2.5-fold increased risk)
  - Malignancy- especially if actively treated with chemotherapy
- C-dif has surpassed MRSA as most common cause of healthcare associated infection

Pathogenesis of CDI

1. CDI spores survive in the environment for long periods of time. Following ingestion, they traverse the acidic environment of the stomach.

3. Altered lower intestine flora (due to antimicrobial use) allows proliferation of *C. difficile* in colon.

4. Toxin A & B Production leads to colon damage +/- pseudomembrane.

2. Spores germinate within the intestine

Sunenshine & McDonald Cleve Clin J Med 2006; 73(2):187-197.

Clostridium difficile- Routes of transmission

► Hands of healthcare personnel, transiently contaminated with spores, and environmental contamination are predicted as main vectors

► Instruments- rectal thermometers etc

► Family members

Clostridium Difficile- Diagnosis

- Who should we test- patients with 3 unformed stools in 24 hours

- Types of stool tests
  - **Enzyme immunoassay.** The enzyme immunoassay (EIA) test is faster than other tests but isn't sensitive enough to detect many infections and has a higher rate of falsely normal tests.
  - **Polymerase chain reaction.** This sensitive molecular test can rapidly detect the C. difficile toxin B gene in a stool sample and is highly accurate.
  - **GDH/EIA.** Some hospitals use a glutamate dehydrogenase (GDH) in conjunction with an EIA test. GDH is a very sensitive assay and can accurately rule out the presence of C. difficile in stool samples.
  - **Cell cytotoxicity assay.** A cytotoxicity test looks for the effects of the C. difficile toxin on human cells grown in a culture. This type of test is sensitive, but it is less widely available, more cumbersome to do and requires 24 to 48 hours for test results. Some hospitals use both the EIA test and cell cytotoxicity assay to ensure accurate results.

Available Tests

Table 1. **Tests Available for Laboratory Confirmation of *Clostridium difficile* Infection***

Test	Description	Sensitivity, %	Specificity, %	Speed of Reports	Cost, $†
EIA	Detects toxin A or toxins A plus B	70–80	>97	Hours	5–17
GDH	Detects a common antigen, not a toxin, of *Clostridium difficile*; immunoassay is preferred over latex agglutination	70–80	<90	Hours	17
qPCR	Detects toxin B or toxin regulator genes; commercial and locally developed tests are available	>90	>97	Hours	7–50
Anaerobic culture for toxigenic *C. difficile*	Detects toxin B	>90	95–97	2 to >3 d	10–22
Direct stool cytotoxin with tissue culture	Detects toxin B	70–80	>97	2 to >3 d	7–13

EIA = enzyme immunoassay; GDH = glutamate dehydrogenase; qPCR = quantitative real-time polymerase chain reaction.
* Adapted from references 6 and 10–13.
† Range of manufacturer's suggested retail prices for 2007–2008 (6, 12).

Guidance from the American Society for Microbiology

- Toxin A/B enzyme immunoassays have low sensitivity and should not be used as stand alone tests.[1]

- Highly sensitive screening tests like glutamate dehydrogenase antigen assays (GDH) should have positive results confirmed.

- Nucleic acid amplification that detects *C. difficile* toxin genes may be used as a stand alone test.

- Repeat testing, testing of formed stool, and testing for cure should be avoided.[2]
  Regardless of testing method, ensure appropriate testing to optimizing test performance!

1. Am Soc Microbiol, 2010.   2. Dubberke et al. Infect Control Hosp Epidemiol 2014; 35 (6):628-645.

Clostridium Difficile- Diagnosis

- Important to remember, if CDI is suspected, do not delay treatment. Empiric treatment is extremely important in preventing complications

- Do not perform repeat testing (within 7 days) during the same episode
  - Increases diagnostic yield only 2%
  - If epidemic is suspected- repeat testing may be warranted vs empiric treatment

Guidance for Appropriate Testing

- Tools that guide clinical decision making, such as algorithms, can assist in ensuring appropriate testing

Diagnostic Algorithm for C. difficile Infection:

Patient with clinically-significant diarrhea (3 or more loose stools per day for at least 1 to 2 days)? — NO → Observe for 24 hrs to assess for persistence of symptoms. Do not order test for C. difficile.

YES ↓

Has patient been taking laxatives over the past 24-48 hours? — YES → Stop laxative and gauge clinical response prior to ordering C. difficile testing.

NO ↓

Enter order for a single stool specimen to be tested for C. difficile. Place patient on empiric Contact Precautions while awaiting results.

C. difficile test results positive? — NO → Alternative diagnosis as cause of diarrheal symptoms made?

YES ↓   YES →

Continue treatment and Contact Precautions. Do not send follow-up C. difficile test (i.e. as a test of cure)

NO → Stop Contact Precautions

If C. difficile strongly suspected despite one negative test, a second test may be sent vs. empiric treatment for C. difficile infection.

Example of a CDI decision tool from Vanderbilt University Medical Center

1. Dubberke et al. Infect Control Hosp Epidemiol 2014; 35(6):628-645.
2. Vanderbilt University Medical Center:
   http://www.mc.vanderbilt.edu/documents/infectioncontrol/files/Guidance%20for%20Providers%20FINAL%202011.pdf

17

Fulminant Clostridium Difficile Infection

▶ In prior guidelines this was referred to severe, complicated CDI

▶ Hypotension
▶ Shock
▶ Ileus
▶ Megacolon

▶ Important to identify early because treatment is different initially

Infection prevention and control

- ▶ Accommodate patients with CDI in a private room with a dedicated toilet to prevent transmission
- ▶ Healthcare personnel must use gloves and gowns upon entry to a room of a patient with CDI
- ▶ These precautions should be instituted if CDI suspected while testing completed
- ▶ Continue contact precautions for 48 hours after resolution of diarrhea
- ▶ Hand washing prior and after patient contact is required. If direct contact with stool, handwashing with soap and water preferred
- ▶ Patient should wash hands and shower when able
- ▶ Disposable equipment should be used if possible and reusable equipment should be thoroughly cleaned sporicidal disinfectant

Infection prevention and control

- ▶ Minimize the frequency and duration of high risk antibiotic therapy
  - ▶ Fluoroquinolones, clindamycin, cephalosporins
  - ▶ Most institutions should have antibiotic stewardship program
- ▶ Proton pump inhibitors
  - ▶ There is an epidemiologic risk associated with PPI and CDI
  - ▶ Minimize use in high risk patients
  - ▶ Insufficient evidence for discontinuation of PPI's
- ▶ Probiotics- Insufficient evidence that they reduce CDI
  - ▶ Does reduce antibiotic associated diarrhea

Treatment

- Discontinue therapy with the inciting antibiotic agent as soon as possible
  - Evidence shows this will decrease clinical response and increase recurrence rates

- Antibiotic therapy for CDI should. Be started empirically for situations where a substantial delay in laboratory confirmation is expected or severe disease

Treatment

- Vancomycin or fidaxomicin is now first line
  - Vanco 125mg PO QID
  - Fidaxomicin 200mg PO BID
  - Treat for 10 days

- Prior guidelines used disease severity to guide treatment decisions
  - Studies since then have showed decreased response and high recurrence in metronidazole groups

Fulminant Clostridium Difficile Infection

- Initial treatment of choice- Vancomycin 500mg PO QID
  - Metronidazole 500mg IV q 8 hours

- If ileus present- Vancomycin 500mg in 100mL NS per rectum q 6 hours
  - Metronidazole 500mg IV q 8 hours

- If ileus or toxic megacolon patient should admitted to ICU with surgical consultation
  - Surgery of choice- subtotal colectomy with rectal sparing
  - Diverting loop ileostomy with colonic lavage may lead to improved outcomes
  - Rising WBC (>25,000) or rising lactate level is associated with high mortality and if occurs early surgery indicated

Recurrent Clostridium Difficile Infection

- Prior guidelines state repeat C-dif treatment with same regimen as initial infection
- Now...

- First recurrence treated with one of the following
  - Vancomycin taper/pulse dosing
  - Fidaxomicin 200mg BID x 10 days
  - Vancomycin can be used in a standard 10 day treatment if metronidazole was used initially
- If additional recurrence occurs-
  - Vancomycin taper/pulse dosing
  - Standard Vancomycin followed by rifaximin 400mg for 20 days
  - Fecal transplant

Vancomycin taper/pulse dose

- 125mg QID for 10-14 days then
- 125mg BID for 7 days then
- 125mg daily for 7 days then
- 125mg q2-3 days for 2-8 weeks

- Mechanism- C. Difficile vegetative forms will be kept in check while allowing restoration of normal microbiota

Fecal Microbiota Transplant

- Patient with recurrent have significant disruption of the intestinal microbiome diversity and decreased bacterial population numbers
- Instillation of processed stool collected from a healthy donor into the intestinal tract of patients with recurrent CDI
  - Effective 77-100% depending on route of instillation
  - Studies of route of transmission and long term consequences are ongoing
- The designated stool donor should undergo screening of blood and feces prior to the stool donation
  - Disqualifying factors- antibiotic in prior 3 months, IBD, malignancy, chronic infection, autoimmune disease, immunosuppressive medications
- Typically induction course of 3-4 days of vancomycin prior

Probiotics

▶ Several have shown promise in preventing CDI recurrence but none have shown reproducible efficacy in clinical trials

▶ Saccharomyces boulardii

▶ Lactobacillus

Cholestyramine

▶ In patients with refractory disease give 4g PO 3-4 times daily
▶ Works by binding Toxin A/B

▶ Use in adjunct with antibiotics- Must separate by 3 hours as it will bind

▶ Can continue for several weeks after antibiotic regimen if needed.

Clostridium difficile

▶ Following treatment, there is no reason to retest stool as patient may have colonized and would result in unnecessary treatment

▶ May discontinue contact precautions once diarrhea free for 48 hours

▶ Antibiotic overuse has led to increase in Clostridium difficile colitis and recurrence.
  ▶ Limiting usage through self monitoring and antibiotic stewardship programs

Summary

▶ Review your facilities diagnostic studies and understand the S/S of each

▶ Only test patient's with diarrhea

▶ Initiate contact precautions once CDI suspected

▶ First line treatment is now vancomycin

▶ Prevention is key- contact precautions, hand washing, limit antibiotic usage

Questions…

References

2007 Guideline for isolation precautions: preventing transmission of infectious agents in healthcare settings. Centers for Disease Control and Prevention Web site. http://www.cdc.gov/hicpac/2007IP/2007isolation Published 2007. Updated December 9, 2010. Accessed February 24, 2016.

Abad C., Fearday A., & Safdar N. (2010). Adverse effects of isolation in hospitalized patients. *J Hosp Infect*, *76*, 97-102.

Ahyow L., Lambert P., Jenkins D., Neal K., & Tobin M. (2013). Occupancy rates and hospital-acquired *Clostridium difficile* infection: A cohort study. *Infect Control Hosp Epidemiol, 34*, 1062-1069.

A practical guidance document for the laboratory detection of toxigenic *Clostridium difficile* infection. American Society of Microbiology Web site. http://www.asm.org/images/pdf/Clinical/clostridiumdifficile9-21.pdf Published September 21, 2010.   Accessed February 24, 2016.

Berhe M., Edmond M., Bearman G. (2006). Measurement and feedback of infection control process measures in the intensive care unit: Impact on compliance. *Am J Infect Control, 34(8)*, 537-539.

Bliss D.Z., Johnson S., Savik L., Clabots C.R., Willard K., Gerding D.N. (1998). Acquisition of *Clostridium difficile* and *Clostridium difficile* associated disease in hospitalized patients receiving tube feeding.   *Ann Intern Med, 129*, 1011-1019.

Bobulsky G.S., Al-Nassir W.N., Riggs M.M., Sethi A.K., & Donskey C.J. (2008). *Clostridium difficile* skin contamination in patients with *C. difficile*-associated disease. *Clin Infect Dis, 46(3)*, 447-450.

References

Boyce J.M., Havill N.L., Havill H.L., Mangione E., Dumigan D.G., Moore B.A. (2011). Comparison of fluorescent marker systems with 2 quantitative methods of assessing terminal cleaning practices. *Infect Control Hosp Epidemiol*, 32(12), 1187-1193.

Boyce J.M., Ligi C., Kohan C., Dumigan D., Havill N.L. (2006). Lack of association between the increased incidence of *Clostridium difficile*-associated disease and the increasing use of alcohol-based hand rubs. *Infect Control Hosp Epidemiol*, *27(5)*, 479-483.

Buendgens L., Bruensing J., Matthes M., et al. (2014). Administration of proton pump inhibitors in critically ill patients is associated with increased risk of developing *Clostridium difficile*-associated diarrhea. *J Crit Care, 696*, e11-15.

Carling P. (2013). Methods for assessing the adequacy of practice and improving room disinfection. *Am J Infect Control*, *41*, S20-25.

Carrico, R. M., Rebmann, T., English, J. F., Mackey, J. Cronin, S. N. (2008). Infection prevention and control competencies for hospital based healthcare personnel. *Am J Infect Control*, 36; 691-701.

Chang H.T., Krezolek D., Johnson S., Parada J.P., Evans C.T., Gerding D.N. (2007). Onset of symptoms and time to diagnosis of *Clostridium difficile*-associated disease following discharge from an acute care hospital. *Infect Control Hosp Epidemiol*, 28(8), 926-931.

Cimiotti J.P., Aiken L.H., Sloane D.M., Wu E.S. (2012). Nurse staffing burnout, and health care associated infection. *Am J Infect Control, 40(6), 486-490*.

References

Dancer S.J., Kirkpatrick P., Corcoran D.S., Christison F., Farmer D., Robertson C. (2013). Approaching zero: temporal effects of a restrictive antibiotic policy on hospital-acquired *Clostridium difficile*, extended-spectrum β-lactamase-producing coliforms and methicillin-resistant *Staphylococcus aureus*. *Int J Antimicrob Agents*, *41(2)*, 137-142.

DeBono, S., Heling, G., Borg, M. A. (2014). Organizational culture and its implications for infection prevention and control in healthcare settings. *J Hosp Infect*, *86*; 1-6.

Dubberke E.R., Carling P., Carrico, R., et al. (2014). Strategies to Prevent *Clostridium difficile* Infections in Acute Care Hospitals: 2014 Update. *Infect Control Hosp Epidemiol*, 35(6), 628-645.

Dubberke E.R. & Olsen M.A. (2012). Burden of *Clostridium difficile* on the Healthcare System. *Clin Infect Dis*, 55, S88-92.

Dubberke E.R., Reske K.A., Noble-Wang J., et al. (2007). Prevalence of *Clostridium dfficile* environmental contamination and strain variability in multiple health care facilities. *Am J Infect Control, 35*, 315- 318.

Gonzalez E., Nandy P., Lucas A.D., Hitchins V.M. (2015). Ability of cleaning-disinfecting wipes to remove bacteria from medical device surfaces. *Am J Infect Control, 43*, 1331-1335.

References

Gould C.V., Edwards J.R., Cohen J., et al. (2013). Effect of nucleic acid amplification testing on population-based incidence rates of *Clostridium difficile* infection. *Clin Infect Dis*, , 57, 1304-1307.

Griffiths P., Renz A., Hughes J., Rafferty A.M. (2009). Impact of organization and management factors on infection control in hospitals: a scoping review. *J Hosp Epidemiol, 73*, 1-14.

Gudnadottir U., Fritz J., Zerbel S. (2013). Reducing healthcare associated infections: Patients want to be   engaged and learn about infection prevention. *Am J Infect Control, 41(11)*, 955-958.

Guidance to providers: Testing for C. difficile infection. Vanderbilt University Medical Center Web site.

http://www.mc.vanderbilt.edu/documents/infectioncontrol/files/Guidance%20for%20Providers%20FINAL%202011.pdf Published August 31, 2011. Accessed February 24, 2016.

Guideline for disinfection and sterilization in healthcare facilities, 2008. Centers for Disease Control and Prevention Web site. http://www.cdc.gov/hicpac/Disinfection_Sterilization/acknowledg.html.

Updated December 29, 2009. Accessed February 24, 2016.

Guidelines for Environmental Infection Control in Health Care Facilities, 2003. Centers for Disease Control and Prevention Web site. http://www.cdc.gov/hicpac/pubs.html Updated May 1, 2015. Accessed February 24, 2016.

References

HCUP Projections: Clostridium difficile Hospitalizations 2001 to 2013. HCUP Web site.   http://hcup-us.ahrq.gov/reports/projections/2014-01.pdf. Published April 9, 2014. Accessed February 24, 2016.

Hensgens M.P., Goorhuis A., Dekkers O.M., Kuiiper E.J. (2012). Time interval of increased risk for *Clostridium difficile* infection after exposure to antibiotics. *J Antimicrob Chemother*, 67(3), 742-748.

Howell R., Novack V., Grgurich P., Souilliard D., Novack L., Pencina M., Talmor D. (2010). Iatrogenic gastric acid suppression and the risk of nosocomial *Clostridium difficile* infection. *Arch Int Med*, 170(9), 784-790.

Hsu J., Abad C., Dinh M., Safdar N. (2010). Prevention of endemic healthcare-associated Clostridium difficile infection: reviewing the evidence. *Am J Gastroenterol, 105(11)*, 2327-2339.

Impact of Antibiotic Stewardship Programs on *Clostridium difficile (C. diff)* infections. Centers for Disease   Control and Prevention Web site. http://www.cdc.gov/getsmart/healthcare/evidence/asp-int-cdiff.html Updated May 13, 2015. Accessed February 24, 2016.

Isaacson D., Haller B., Leslie H., Roemer M., Winston L. (2015). Novel handwashes are superior to soap and water in removal of *Clostridium difficile* spores from the hands. *Am J Infect Control*, 43, 530-532.

References

Johnson S., Gerding D.N., Olson M.M., Weiler M.D., Clabots C.R., Peterson L.R. (1990). Prospective, controlled study of vinyl glove use to interrupt *Clostridium difficile* nosocomial transmission. *Am J Med,* 88(2), 137-140.

Kombuj M., Sheahan A., Sun J., et al. (2016) Transmission of *Clostridium Difficile* during hospitalization for allogenic stem cell transplant. *Infect Control Hosp Epidemiol*, 37, 8-15.

Kufelnicka, A. M., Kim, T. J. (2011). Effective utilization of evolving methods for laboratory diagnosis of Clostridium difficile infection. *Clin Infect Dis*, 52; 1451-1452.

Kundrapu, S., Sunkesula, V., Jury, I., Deshpande, A., Donskey, C. (2014). A randomized trial of soap and water hand wash versus alcohol hand rub for removal of Clostridium difficile spores from hands of patients. *Infect Control Hosp Epidemiol*, 35; 204-205.

Lessa F., Mu Y., Bamberg W., Beldavs Z.G., et al. (2015). Burden of *Clostridium difficile* Infection in the United States. *N Engl J Med*, 372 (9), 825-834.

Linney S., Fernandes T., Einarson T., Sengar A. Walker J.H., Mills A. (2010). Association between use of proton pump inhibitors and a *Clostridium difficile*-associated disease outbreak: case-control study. *The Canadian Journal of Hospital Pharmacy, 63(1),* 31-37.

Litvin M., Reske K.A., Mayfield J., et al. (2009). Identification of a pseudo-outbreak of *Clostridium difficile* Infection (CDI) and the effect of repeated testing, sensitivity, and specificity on perceived prevalence of CDI. *Infect Control Hosp Epidemiol*, 30, 1166-1171.

References

Magill S.S, Edwards J.R., Bamberg W., et al. Emerging Infections Program Healthcare-Associated Infections and Antimicrobial Use Prevalence Survey Team. (2014). Multi State Point-Prevalence Survey of Health Care Associated Infections. *N Eng J Med, 370, 1198-1208.*

Mayfield J.L., Leet T., Miller J., Mundy L.M. (2003). Environmental control to reduce transmission of *Clostridium difficile. Clin Infect Dis*, 31(4), 995-1000.

McDonald L.C., Killgore G.E., Thompson A., et al. (2005). An epidemic, toxin gene-variant strain of *Clostridium difficile. N Eng JMed*, 353(23), 2433-2441.

McGukin M. & Govednik J. (2013) Patient empowerment and hand hygiene. *J Hosp Infect*, 84, 191-199.

Moore G., Smyth D., Singleton J., Wilson P. (2010). The use of adenosine triphosphate bioluminescence to assess the efficacy of a modified cleaning program implemented within an intensive care setting. *Am J Infect Control*, 38, 617-622.

Mulvey D., Redding P., Robertson C., Woodall C., Kingsmore P., Bedwell D., Dancer S.J. (2011). Finding a benchmark for monitoring hospital cleanliness. *J Hosp Infect, 77,* 25-30.

Options for evaluating environmental cleaning. Centers for Disease Control and Prevention Web site. http://www.cdc.gov/hai/toolkits/Evaluating-Environmental-Cleaning.html. Published December 2010. Updated August 14, 2014. Accessed February 24, 2016.

Orenstein, R., Aronhalt, K., McManus, J. E. Fedraw, L. A. (2011). A targeted strategy to wipe out *Clostridium difficile. Infect Control Hosp Epidemiol, 32;* 1137-1139.

References

Oughton M.T., Loo V.G., Dendukuri N., Fenn S., Libman M.D. (2009). Hand hygiene with soap and water is superior to alcohol rub and antiseptic wipes for removal of *Clostridium difficile*. *Infect Control Hosp Epidemiol*, 30(10), 939-944.

Pepin J., Saheb N.B., Coulombe M.A . et al. (2005). The emergence of fluoroquinolones as the predominant risk factor for *Clostridium difficile*-Associated diarrhea: A cohort study during an epidemic in Quebec. *Clin Infect Dis, 41(9),* 1254-1260.

Peterson L.R., Robicsek A. (2009). Does my patient have *Clostridium difficile* infection? *Ann Int Med*, 151(3), 176-179.

Pincock T., Bernstein P., Warthman S., Holst E. (2012). Bundling hand hygiene interventions and measurement to decrease healthcare associated infections. *Am J Infect Control*, 40, S18-27.

Planche T., Aghaizu A., Holliman R. et al. (2008). Diagnosis of *Clostricium difficle* infection by toxin detection: a systematic review. *Lancet Infect Dis*, 8, 777-784.

Riggs M.M., Sethi A.K., Zabarsky T.F., Eckstein E.C., Jump R.L., Donskey C.J. (2007).Asymptomatic carriers are a potential source for transmission of epidemic and non-epidemic *Clostridium difficile* strains among long-term care facility residents. *Clin Infect Dis*, 45(8), 992–998.

Rutala W.A., Gergen M.F., Weber, D.J. (2012). Efficacy of different cleaning and disinfection methods against *Clostridium difficile* spores: importance of physical removal versus sporicidal inactivation. *Infect Control Hosp Epidemiol*, 33(12*)*, 1255-1258.

See I., Mu Y., Cohen J., Beldavs Z.G. et al. (2014). NAP1 strain type predicts outcomes from *Clostridium difficile* Infection. *Clin Infect Dis*, 58(10), 1394-1400.

39

References

Sethi A.K., Al-Nassir W.N., Nerandzic M.M., Bobulsky G.S., Donskey C.J. (2010). Persistence of skin contamination and environmental shedding of *Clostridium difficile* during and after treatment of C. difficile infection. *Infect Control Hosp Epidemiol, 31(1)*, 21-27.

Shama G. & Malik D.J. (2013). Uses and abuses of rapid bioluminescence based ATP assays. *Int J Hyg Environ Health*, 216, 1115-1125.

Shaughnessy M.K., Micielli R.L., DePestel D.D. Arndt J., Strachan C.L., Welch K.B., Chenoweth C.E. (2011). Evaluation of hospital room assignment and acquisition of *Clostridum difficile* infection *Infect Control Hosp Epidemiol*, 32, 201-206.

Sinkowitz-Cochran R.L., Burkitt K.H., Cuerdon T., et al.(2012). The associations between organizational culture and knowledge, attitudes, and practices in a multicenter Veterans Affairs quality improvement initiative to prevent methicillin-resistant *Staphylococcus aureus*. *Am J Infect Control*, 40, 138-143.

Sinkowitz-Cochran R.L., Garcia-Williams A., Hackbarth A.D., et al. (2012). Evaluation of organizational culture among different levels of healthcare staff participating in the Institute for Healthcare Improvement's 100,000 Lives Campaign. *Infect Control Hosp Epidemiol*, 33, 135-143.

Sitzlar, B., Deshpande, A., Fertelli, D., Kundrapu, S., Sethi, A., Donskey, C. (2013). An environmental disinfection odyssey: Evaluating of sequential interventions to improve disinfection of *Clostridium difficile* isolation rooms. *Infect Control Hosp Epidemiol, 34;* 459-465.

Slayton R.B., Toth D., Lee B.Y. et al. (2015). Vital Signs: Estimated Effects of a Coordinated Approach for Action to Reduce Antibiotic-Resistant Infections in Health Care Facilities - United States. *Morb Mort Week Rep,* 64 (30), 826-831.

40

References

Stabler R.A., Dawson L.F., Phua L.T., Wren B.W. (2008). Comparative analysis of BI/NAP1/027 hypervirulent strains reveals novel toxin B-encoding gene (tcdB) sequences. *J Med Micro,* 57(6), 771-775.

Stevens, V., Dumyati, G., Brown, J., van Wijngaarden, E. (2011). Differential risk of *Clostridium difficile* infection with proton pump inhibitor use by level of antibiotic exposure. *Pharmacoepidemiologic Drug Safety, 20*; 1035-1042.

Sunenshine R.H. & McDonald L.C. (2006). *Clostridium difficile*-associated disease: new challenges from an established pathogen. *Cleve Clin J Med, 73(2),* 187-197.

Valiquette L., Cossette B., Garant M., Diab H., Pepin J. (2007). Impact of a reduction in the use of high-risk antibiotics on the course of an epidemic of *Clostridium difficile* associated disease caused by the hypervirulent ANP1/027 strain. *Clin Infect Dis, 45,* S112-121.

Warny M., Pepin J., Fang A., et al. (2005). Toxin production by and emerging strain of *Clostridium difficile* associated with outbreaks of severe disease in North America and Europe. *The Lancet, 366(9491),* 1079-1084.

Weber D. & Rutala W. (2011). The role of the environment in transmission of *Clostridium difficile* transmission in healthcare facilities. *Infect Control Hosp Epidemiol, 32,* 207-209.

Wilcox M.H., Fawley W.N., Wigglesworth N., Parnell P., Verity P., Freeman J. (2003). Comparison of the effect of detergent versus hypochlorite cleaning on environmental contamination and incidence of *Clostridium difficile* infection. *J Hosp Infect, 54(2),* 109-114.